Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, CPI-0610, JAKi treatment-naive, MANIFEST-2, myelofibrosis, pelabresib, ruxolitinib, OUTCOMES, EFFICACY, DISCONTINUATION, MOMELOTINIB, BROMODOMAIN, SAFETY, TRIAL, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials, Phase III as Topic, Humans, Janus Kinase Inhibitors, Nitriles, Primary Myelofibrosis, Pyrazoles, Pyrimidines, Randomized Controlled Trials as Topic, Treatment Outcome, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

Abstract:

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, typically associated with disease-related symptoms, splenomegaly, cytopenias and bone marrow fibrosis. Patients experience a significant symptom burden and a reduced life expectancy. Patients with MF receive ruxolitinib as the current standard of care, but the depth and durability of responses and the percentage of patients achieving clinical outcome measures are limited; thus, a significant unmet medical need exists. Pelabresib is an investigational small-molecule bromodomain and extraterminal domain inhibitor currently in clinical development for MF. The aim of this article is to describe the design of the ongoing, global, phase III, double-blind, placebo-controlled MANIFEST-2 study evaluating the efficacy and safety of pelabresib and ruxolitinib versus placebo and ruxolitinib in patients with JAKi treatment-naive MF. Clinical Trial Registration: NCT04603495 (ClinicalTrials.gov).